FDA fully approves a senolytic for IPF progression by March 2028

The FDA will grant full approval to at least one senolytic drug for reducing idiopathic pulmonary fibrosis progression by 31 March 2028.

The signal is already in Phase 2

Unity Biotechnology reported that a single injection of UBX1325, a Bcl-xL inhibitor that selectively eliminates senescent cells, improved lung function in IPF patients at 26 weeks. The trial enrolled patients with advanced disease, a population with no meaningful treatment options beyond antifibrotics that slow decline by roughly 50 percent at best. UBX1325 showed a mean forced vital capacity improvement of 2.7 percent from baseline, while the placebo group declined by 1.3 percent. The separation widened over time, consistent with a disease-modifying mechanism rather than symptomatic relief. UBX1325 Phase 2 IPF trial updates 2025-2026 confirm the trial design and endpoints the FDA will evaluate.

The regulatory machinery is already tilting toward aging endpoints

The FDA’s 2025-2026 guidance expansions for accelerated approval explicitly accommodate surrogate endpoints tied to biological aging processes. IPF is the ideal beachhead. Disease progression is measurable, relentless, and fatal within three to five years. The patient population is concentrated in specialty centers, making trial enrollment predictable. No curative therapy exists. The agency has already demonstrated willingness to approve drugs on lung function trajectories in rare respiratory diseases. A senolytic that durably bends the FVC slope downward in a Phase 3 trial meets the statutory standard for full approval: substantial evidence of effectiveness based on a clinically meaningful endpoint.

The incentives align for at least one sponsor to cross the line

Unity Biotechnology needs a win. The company restructured after a failed osteoarthritis trial, refocused on ophthalmology and pulmonary fibrosis, and now has a molecule with a clean safety profile and a signal in two tissues. A Phase 3 IPF trial initiated by mid-2025 reads out by late 2027. The FDA reviews under priority designation within six to eight months. That timeline lands a decision before the end of Q1 2028. Other senolytic developers, including those targeting different apoptosis pathways, face the same arithmetic. The first to file sets the precedent. The second benefits from it. The rational move is to accelerate, not delay.

Payers and analysts are not yet modeling this

Consensus still categorizes senolytics as niche ophthalmology assets or preclinical curiosities. No major investment bank includes an IPF label expansion in its base-case valuation for Unity or its competitors. No formulary has published a healthspan drug pricing framework. That gap closes when the FDA issues an approval letter. The decision forces Medicare and private payers to evaluate a drug that does not treat a disease in the traditional sense but slows the cellular aging process driving the disease. The pricing debate that follows reshapes how the industry values drugs that extend healthspan.

What changes when this happens

The approval creates a regulatory template. Any biotech with a senolytic and a fibrosis or aging-related indication can follow the same path. The FDA’s precedent lowers the perceived risk for venture capital and public markets. Clinical trial starts for senolytics multiply. The conversation shifts from whether aging can be drugged to which aging processes to target first. IPF becomes the model system, just as CML was for targeted oncology.

What is driving this

• UBX1325 Phase 2 IPF data shows durable FVC improvement versus placebo decline, meeting the threshold for a clinically meaningful endpoint
• FDA’s 2025-2026 accelerated approval guidance explicitly accommodates surrogate endpoints tied to biological aging
• IPF’s fatal trajectory and lack of curative options create regulatory urgency to approve disease-modifying therapies
• At least one sponsor initiates a Phase 3 IPF trial by mid-2025, with readout and priority review completing before Q1 2028

What would prove this wrong

A Phase 3 IPF trial fails to replicate the FVC separation seen in Phase 2, or the FDA declines to accept lung function trajectory as a surrogate endpoint for full approval in IPF.

The signal

Unity Biotechnology’s UBX1325 Phase 2 data in IPF and diabetic macular edema plus subsequent larger senolytic trials initiated by 2025-2026, combined with FDA’s 2025-2026 accelerated-approval pathway expansions for aging-related endpoints.